Loxo Oncology Inc

Most Recent

  • uploads///Analysts Reco Ignyta
    Company & Industry Overviews

    Analyst Recommendations for Ignyta and Its Peers in January 2018

    Of the four analysts covering Ignyta in January 2018, all of them have given the stock a “hold” rating. The mean rating for the stock is 3.0 with a target price of $28.

    By Kenneth Smith
  • uploads///SALES ESTIMATES
    Earnings Report

    Array BioPharma Missed Sales Estimates for Q4 2018

    Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.

    By Sarah Collins
  • uploads///Entrectinib profile
    Company & Industry Overviews

    A Close Look at Ignyta’s Licensing Agreement

    Ignyta (RXDX) entered into a licensing agreement with Nerviano Medical Sciences in which Ignyta has exclusive global rights to develop and commercialize entrectinib.

    By Kenneth Smith
  • uploads///Ignyta RD Expenses
    Company & Industry Overviews

    Inside Ignyta’s Financial Performance

    Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?

    In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years

    Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019

    Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts Recommending for Eli Lilly and Loxo Oncology?

    Eli Lilly and Company (LLY) has entered into an agreement to acquire Loxo Oncology (LOXO) for a net consideration of $7.2 billion.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Why Loxo Oncology Has Surged More than 65% Today

    Earlier today, American pharmaceutical giant Eli Lilly and Company (LLY) announced its acquisition of Loxo Oncology (LOXO).

    By Jitendra Parashar
  • uploads///dna _
    Company & Industry Overviews

    Why Endocyte’s Stock Price Rose 11.4% Yesterday

    Today, Endocyte stock is trading at $19.16, which reflects ~1.43% growth from yesterday’s closing price of $18.89. Here’s why.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.

    By Daniel Collins
  • uploads///cell
    Company & Industry Overviews

    Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18

    On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.

    By Daniel Collins
  • uploads///ARRY Revenue Trend
    Company & Industry Overviews

    Array BioPharma’s Financial Performance

    The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s ARRY-382 and ARRY-797

    Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.

    By Kenneth Smith
  • uploads///ARWR revenue forecast
    Company & Industry Overviews

    Taking Stock of Arrowhead Pharmaceuticals’ Financial Performance

    In 2017, Arrowhead Pharmaceuticals (ARWR) generated revenue of $31.4 million compared to $158,000 in 2016. This increase was attributable to the upfront payments Arrowhead received from Amgen.

    By Kenneth Smith
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Hepatitis B virus life cycle
    Company & Industry Overviews

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

    By Kenneth Smith
  • uploads///ARWR Drug Pipeline
    Company & Industry Overviews

    Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

    Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.

    By Kenneth Smith
  • uploads///ARWR Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Arrowhead and Its Peers

    Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.